Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab + tremelimumab. - Casadei-Gardini A; Yip TC; Vitale A; Rossari F; Tada T; Suda G; Shimose S; Kudo M; Cheon J; Finkelmeier F; Lim HY; Presa J; et al. (European journal of cancer (Oxford, England : 1990), 2026)